​Effective March 29, 2024, warfarin (Coumadin^®), dabigatran (Pradaxa^®), apixaban (Eliquis^®) and rivaroxaban (Xarelto^®) have been added to the ADAP formulary.

Anticoagulants are medications used to prevent blood clots. Blood clots are usually a protective response to injury that promote healing, but blood clots can also cause acute medical illness and death if they occur in inappropriate locations. Anticoagulant treatment is recommended to prevent blood clot formation in patients with certain comorbid medical conditions including atrial fibrillation, valvular cardiac disease, and a history of deep vein thrombosis or pulmonary embolism. These medical conditions are common. It is estimated that one to two percent of adults in the United States have chronic atrial fibrillation and that 200,000 people develop deep vein thromboses per year. In addition, people with human immunodeficiency virus (HIV) have an increased risk of both atrial fibrillation and deep vein thrombosis. University of California, San Francisco researchers have estimated that people with HIV have an 80 percent higher prevalence of atrial fibrillation than the general population and as the prevalence of atrial fibrillation increases with age, the number of people with HIV who develop atrial fibrillation is also expected to increase. Fortunately, anticoagulant treatment is beneficial for these medical conditions and the addition of these anticoagulant medications provides patients with ADAP options to reduce the risk of stroke in people with atrial fibrillation and to reduce the risk of recurrent thrombosis in people with deep vein thrombosis.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of warfarin (Coumadin^®), dabigatran (Pradaxa^®), apixaban (Eliquis^®) and rivaroxaban (Xarelto^®).

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov ).

Thank you,